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Abstract
The treatment of hepatitis C has entered a new era since the advent of curative pharmaceuticals. As policy, government
and civil society assemble in response, there are still gaps to be addressed. The Manifesto on Hepatitis C and Drug Use,
launched in Berlin during the Correlation Hepatitis C Initiative conference in October 2014, was formulated and endorsed
by many key organizations in the hepatitis field. The Manifesto takes strides to pinpoint shortcomings in hepatitis action
oriented towards the population most affected by the hepatitis C virus (HCV): active drug users.
Despite a considerable amount of evidence that active drug users are disproportionately affected by HCV, barriers to care
remain. Engagement with representatives of communities of people who inject drugs (PWID) is imperative in order to
effectively create guidelines which reflect reality. Unfortunately, widespread systemic stigmatization and lack of trust
between affected communities, decision-makers and healthcare professionals have reproduced this divide. The Berlin
Manifesto has identified a disconnect between evidence and action which must be answered.
In this roundtable discussion, experts from diverse parts of the hepatitis community have contributed their perspectives
and experience on access to prevention, testing, and treatment for HCV in PWID. The authors discuss relevant topics such
as realities of access to HCV treatment in the United Kingdom, interventions of a regional network of active drug users in
Europe and lack of PWID involvement in government policy in Catalonia. Collectively they challenge the neglect of HCV
in PWID by many decision-makers and health care professionals and promote a scale-up of integrated prevention and
treatment strategies focusing on this population. The authors’ conclusions aim to clarify the discourse on hepatitis in
order to prevent disease, save lives and work towards eventual hepatitis elimination.
The aims of the Correlation Berlin Hepatitis C
Manifesto: did dreams come true?
Eberhard Schatz, Katrin Schiffer, Correlation Network,
Amsterdam, The Netherlands
The Manifesto on Hepatitis C and Drug Use was
launched in Berlin during the Correlation Hepatitis C
Initiative conference in October 2014 [1]. Its develop-
ment was a collaborative process involving several key
experts from civil society. Additionally, it was endorsed
by a broad range of leading organizations in the field,
including the European AIDS Treatment Group, the
European Association for the Study of the Liver
(EASL), the European Liver Patients Association, Harm
Reduction International, the International Network of
People Who Use Drugs and the World Hepatitis Alliance.
The Manifesto is an urgent call to policy-makers and
health care professionals to pay specific attention to the
needs of the largest hepatitis C virus (HCV) patient group:
people who inject drugs (PWID). This manifesto states
that, despite evidence that treating (active) drug users is
effective, and despite the fact that HCV treatment guide-
lines from EASL and WHO to the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) and
European Centre for Disease Prevention and Control
(ECDC) [2, 3, 4] recommend treatment for this target
group, barriers to access remain. A Correlation survey
pointed out that many countries in the European Union
continue not to have hepatitis strategies and/or action
plans, including measures for the treatment of PWID [5].
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The Manifesto places HCV treatment in the broader
context of integrated services and emphasizes the need
to add harm reduction services to the cascade of treat-
ment, including the safeguarding of full coverage and
funding. Furthermore, it calls for the involvement of
drug users not only in the execution of peer and preven-
tion programs but also within decision-making processes
like the development of programs. Above all, the Manifesto
accentuates the complexities of stigma and discrimination
due to the policy of criminalizing drug use(rs), which pro-
vides a major barrier to equal access to health services.
Overall, there is increased awareness of HBV and HCV,
thanks to major efforts from a range of stakeholders at all
levels. Importantly, there is a growing hepatitis advocacy
community, making the quest to eliminate HCV even
more imperative. In this context, the Berlin Manifesto
plays an important role by highlighting the need to focus
on people who use drugs and involve them in meaningful
ways. One telling development is the increasing imple-
mentation of community and low-threshold testing pro-
grams, which reduce the barriers to testing and linkages
to care, when deemed necessary. At the same time, other
developments remain concerning: harm reduction and
community service budgets are constantly cut or, in some
settings, remain non-existent. It seems that the full inte-
gration of harm reduction services into the “treatment”
cascade—which we prefer to call the continuum of care
cascade—is one step too far for many local programs.
The fundamental question today is: after the launch of
the Berlin Manifesto in 2014, and even more import-
antly, the introduction of highly efficient direct-acting
antivirals since then, has the context of PWID and HCV
improved? Understandably, the overall answer is com-
plex. The contributions of this roundtable discussion
provide insights from a range of experts, including a
service provider, researchers, a hepatologist, a govern-
ment official and, importantly, a representative from
the European Network of People Who Use Drugs.
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Drug users as activists: grassroots efforts to give
voice to the drug using community
Mags Maher, European Network of People Who Use
Drugs, London, the United Kingdom
The European Network of People Who Use Drugs
(EuroNPUD) is a regional network of drug user activists
living across Europe who take drugs and represent the
voice of Europe’s drug using community. A grassroots
organization, we focus on drug-related activities that in-
clude human rights, drug policy reform, harm reduction,
meaningful engagement and participation, peer/global
advocacy, coordination, international cooperation, infor-
mation, research and evaluation. We have also estab-
lished communication systems among drug user groups
and activists in the European Union (EU), which is key
to our intelligence gathering and consultation at a grass
roots level.
In short, EuroNPUD provides a vehicle for drug user
activists and groups in the EU to work together to share
best practices, provide mutual aid, offer peer-to-peer
technical support and foster collective action and
network development. Without active drug user in-
volvement, no drug policy or project will accurately
reflect what is happening within the drug using
communities today.
In line with the European Hep C Initiative and their
Berlin Manifesto: Hepatitis C: access to prevention, test-
ing, treatment and care for people who use drugs
(PWUD) [1], we have strongly recommended the devel-
opment and implementation of European and national
hepatitis C virus (HCV) strategies and action plans. We
suggest that they include appropriately funded multidis-
ciplinary approaches for HCV prevention and control
among communities engaged in high-risk behaviors, in-
cluding people who inject drugs. We have provided four
southern European regions, Barcelona, Porto, Athens
and Turin, with start-up grants to strengthen their drug
user networks. The grants will focus on realistic and
achievable interventions that influence hard to reach
drug user groups to join the network as well as access
the treatment interventions and facilities available to
drug users in their regions.
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An area that all four regions have strongly concen-
trated on is the testing of blood borne viruses (including
HCV), which has proved very successful by using a peer-
to-peer support model. This model allows drug users to
work within drug services alongside professionals and
provide interventions ranging from one-to-one support
to drug users considering being tested, to collecting stat-
istical information. The peer support workers, by default,
have a non-judgmental approach to their community,
which builds trust between those drug users accessing a
service and the workers providing it. This platform al-
lows our community members the opportunity to pro-
vide risk reduction information to their peers while
working within a harm reduction framework; ultimately,
we are the experts, and information is trusted when it
comes directly from our community.
Using this model has resulted in a number of drug
users being tested for HCV in North Turin, Italy, and
Porto, Portugal. The experiences show, however, that
there are still large numbers of PWUD who have not
come forward for testing because of the stigma they ex-
perience when entering into a drug service, especially in
such countries as Greece, where the prevalence of HCV
and HIV continues to grow. We strongly think that
prevalence declines if a peer support worker (drug user)
is present but more research is needed to provide clear
evidence.
Risk reduction messages are not infiltrating the drug
using communities for a number of different reasons,
primarily because Greece does not have a drug para-
phernalia law and therefore cannot distribute injecting
equipment; stigma toward drug users is still incredibly
high across southern Europe; and women who are using
drugs live in fear of losing their children, which discour-
ages them from accessing services.
All four southern regions have identified huge gaps in
service provision and are currently engaged in writing a
report on drug users’ views on service provision in their
region. EuroNPUD, in collaboration with Agência Piaget
para o Desenvolvimento (APDES), PRAXIS, Reus Univer-
sity and Grupo de Ativistas em Tratamentos (GAT), is in
discussions on developing a Diploma in Drug Depend-
ency, to be called Project 20/20. The 6-month program
will provide PWUDs with professional qualifications to
work in the field of harm reduction without fear of preju-
dice or stigma. Having PWUDs work within drug services
has already increased the number of drug users accessing
services for several treatment interventions, including
HCV testing, which will contribute toward eliminating
HCV by 2030.
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A revolution for all? Prioritizing HCV treatment
access for people who inject drugs in England
Magdalena Harris, Department of Social and
Environmental Research, London School of Hygiene and
Tropical Medicine, London, the United Kingdom
In 2010, the United Kingdom (UK) achieved the unenvi-
able ranking of 12th among 14 comparable counties for
HCV treatment provision [1], with less than 3 % of those
diagnosed accessing HCV treatment per year [2]. Of the
3 %, very few were people who inject drugs (PWID).
Despite a “pharmacological revolution” in HCV treat-
ment options [3], England’s position on the world treat-
ment access stage is unlikely to change.
2015 has been characterized by dispute and delay in
regard to all-oral direct-acting antiviral (DAA) access in
England. Although expanded DAA access has been rec-
ommended and deemed cost-effective by the National
Institute for Health and Care Excellence (NICE) [4],
NHS England disputes the affordability of this strategy
in a context of fiscal austerity, instead advocating strat-
egies of “watchful waiting” and “treatment sequencing”
[5]. This approach is in stark contrast with those advo-
cated by neighboring countries Scotland, Portugal,
France and Spain, which, in line with an elimination
approach, have scaled up DAA access. NHS England’s
affordability concerns have set the stage for a conserva-
tive prioritization of treatment access by the 22
Operational Delivery Networks (ODN) tasked with this
role. As of February 2016, DAA access is ostensibly ex-
tended to all people with genotype 1 and 4, yet budget-
related “run-rate” 2 restrictions mandate each ODN to
prioritize treatment according to “clinical need” [4]. This
circumspect policy landscape is unlikely to improve
HCV treatment access for PWID—particularly in the
absence of priority population treatment targets.
Given the UK’s prior record of treatment provision for
PWID, priority population targets may be required to at-
tain equity of access. Guidelines are not enough. A 2010
audit of UK hospitals found that many follow formal or
informal policies restricting HCV treatment access for
PWID [6]. Recent qualitative data (see [7] for methods)
capture this inequity:
The criterion for treatment at [hospital] is no drug
use. Within outreach it was stable drug use 2 to 3
times a week. I don’t think that’s even the problem.
I think the problem is getting them to come. Because
they don’t want to come to secondary care. And
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there’s a wait for appointments, so I think they’re likely
to DNA (“do not attend”). (Clinical Nurse Specialist)
Notable is how the hospital’s access policy of “no drug
use,” contravening UK and European guidelines, is mini-
mized and rationalized in regard to the perceived unreli-
ability and disinterest of PWID. Pervasive discrimination
in the hospital environment, such as treatment access
dependent on injecting status, has a recursive effect by
rationing local treatment expectation and, thus, disabling
demand [8]. Outreach models, while ideal in theory, can
be used to rationalize treatment refusal for PWID in
mainstream care, regardless of the availability of local
outreach provision. When the above outreach service
closed due to funding restrictions, PWID in the districts
were bereft of treatment options. For those unable to
demonstrate treatment “readiness” and “stability” (drug
use 2–3 times a week), even outreach was not an option.
Given this context, it is unclear how the benefits of
DAA treatment regimens will affect the lives of PWID.
The elimination vision has been the most successful in
facilitating the rehabilitation of PWID as a treatment-
viable population. While it is regrettable that 1) this re-
habilitation is needed and 2) that it is afforded by
population-health incidence reduction goals rather than
those based on human rights [9], the reluctance of NHS
England to engage with this vision augers poorly for the
attainment of the Berlin Manifesto [10] goals, particu-
larly regarding treatment access for PWID.
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Failing to involve people who inject drugs in
hepatitis C policy definition and implementation
in Catalonia
Xavier Major Roca, Programme on Substance Abuse,
Public Health Agency of Catalonia, Autonomous
Government of Catalonia, Spain
The Berlin Declaration: Hepatitis C: access to preven-
tion, testing, treatment and care for people who use
drugs [1] correctly emphasizes the issue that is key to
addressing the hepatitis C (HCV) epidemic in Europe:
the involvement of the most affected population, people
who inject drugs (PWID), in all stages of policy formula-
tion and implementation.
But this does not happen often. I will explain some sit-
uations that have taken place in Catalonia, Spain, which
I suspect might occur in other European countries:
1) In 2015, an HCV strategy was drawn up by the
Catalan government, with the participation of the
main patient association, which, surprisingly, does
not have any drug user members.
2) The Department of Health has been providing
guidance to clinicians on access to HCV treatment,
but the guidance does not include specific criteria
related to PWID [2]. As a result, inclusion of drug
users in treatment still frequently depends on an
individual doctor’s attitudes toward drug users. In
Catalonia, most coinfected (with HIV) people are
treated by internists, who are much more likely
than hepatologists (who treat monoinfected patients)
to provide HCV treatment to coinfected PWID.
Internists, in contrast to hepatologists, have been
dealing with drug users since the first outbreak of
the HIV epidemic over three decades ago, so they
have learned through experience how to care for
drug users in an effective and nondiscriminatory
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way. Attitudes toward drug users can greatly impinge
on access rates. Clear and specific criteria on drug
users’ access to treatment, such as those mentioned
in the European Association for the Study of the Liver
(EASL) [3] and WHO [4] guidelines, are needed in
Catalonia, but the involvement of drug users,
including lobbying, is paramount in order to
ensure that these guidelines are established.
3) In our consumption rooms, many HIV-positive active
drug users are on antiretroviral therapy, even though
they continue to inject drugs regularly, but few active
drug users infected with HCV have ever been on
HCV antiviral treatment. HIV-positive drug users
have benefited from the strong lobbying efforts of
influential groups and individuals to promote easy
and equitable access to HIV medication. Drug users
who are infected with HCV, however, have not had
the same experience because they are not as well
represented by influential groups as HIV-positive drug
users are, and they also still suffer from stigma within
the general community, which can affect their access
to treatment and, ultimately, their health outcomes.
These disparities might not exist if drug users had
been able to mobilize a committed group of effective
stakeholders as support. Additionally, possibly also a
result of a lack of effective lobbying efforts on the
part of active drug users, the Department of Health
may not have known any representatives from the
drug user community to contact for advice regarding
the needs of these individuals.
These and other examples illustrate the most serious
issues confronting PWID in Catalonia—and possibly
throughout other European countries. In most countries,
drug user organizations are often not well functioning,
in large part because their members have difficult lives
and have little experience in capacity building and gov-
ernance. As a result, it is up to governments and other
members of civil society to engage them in helping de-
velop appropriate policies and programs to ensure that
their needs are met. Any health strategy should, without
a doubt, take into account the views and experiences of
the main target population if it wants to succeed.
One way to address the needs of PWID effectively is
to train hepatologists on drug use, and support them
when they treat drug users. Involving drug users directly
in this training is critical. This approach is a crucial
means of improving linkages to care and, consequently,
increasing treatment uptake. Shared care between drug
care centers and liver specialists is a key issue, and a
new initiative in Copenhagen is a promising model for
the rest of Europe [5].
In 2015, Catalonia made progress toward realizing the
goals of the 2014 Manifesto by establishing a strategy
that includes clear measures to reduce HCV among
PWID. While this was an important step, Catalonia still
has made no progress in seeking input from drug users;
implementation of the strategy, in general, has been
hampered by the economic crisis and current drug
prices; and treatment lags behind.
These constraints notwithstanding, strides forward can
be seen: prevention campaigns such as the commemor-
ation of World Hepatitis Day have been implemented in
drug facilities, and in 2015, Spain took part in the
European HIV testing week, which included hepatitis C
for the first time. And, importantly, additional steps have
been taken to further the prevention, treatment and care
for HCV infected drug users. A hepatitis C rapid test is
now routinely provided by harm reduction services in
Catalonia, and in 2016, research will be carried out on
an antigen test with dried blood spot technology. Guide-
lines have been established for needle and syringe pro-
grams and include recommendations such as: 1) sterile
equipment should be provided based on client needs
without further restrictions, and 2) PWID should be sys-
tematically encouraged to take with them all injection
paraphernalia that they need, along with sterile syringes.
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Hepatitis C treatment for all PWID: myth or reality?
Mojca Maticic, Clinic for Infectious Diseases and Febrile
Illnesses, University Medical Centre Ljubljana, Slovenia
The Berlin Manifesto on HCV and Drug Use calls for
countries to fund, support and implement hepatitis C
virus (HCV) treatment and care services as part of their
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comprehensive national healthcare policies. The Manifesto
also urges pharmaceutical companies and European Union
member states to reach agreement on reducing the price of
new medications and allow the scale-up of treatment [1].
In Europe, three million HCV infected people inject
drugs, with the HCV seroprevalence ranging between
5–90 % [2]. In the last few years, the vast majority of
newly infected people reported injecting drug use as the
mode of infection [3, 4]. In the current era of highly effect-
ive, safe and patient-friendly HCV treatment, speculation
is directed toward the elimination of HCV infection in the
near future [5–7]. Unfortunately, treatment of HCV in
PWID has long been the subject of controversy, although
both adherence to treatment and degree of treatment effi-
cacy among PWID have been shown to be comparable to
those among non-PWID, even in the era of pegylated
interferon (PegIFN) plus ribavirin, which a modeling
study [8–10] proved to enhance prevention of HCV
transmission.
Until 2014, when the Berlin Manifesto on HCV and
Drug Use was launched as part of the European HCV
Initiative [1], key data on HCV management and on the
largest HCV infected group in Europe were sparse and
suggested that only a negligible percentage of either
current or former PWID from high-income countries
were treated for HCV [11]. Published studies, for ex-
ample, have shown that the percentage of these current
or former PWID being diagnosed and entering HCV
treatment ranged from 0.9 to 18 % (median 9.5 %, IQR
3.5–15) [12]. Another systematic review of literature
within the WHO European region pointed to consider-
able knowledge gaps regarding treatment uptake levels
within this population, suggesting that there may be
major differences between and within countries in rela-
tion to treatment availability, drug-using populations in
need of treatment and the existence of integrated health-
care services targeting drug users [13]. For example, re-
ports have shown that various HCV treatment models
have been used across different settings, with varying de-
grees of efficacy achieved. [14–16]. Most importantly,
data reported in 2014 from 33 European countries re-
vealed that there was a lack of existing national strat-
egies, action plans and clinical guidelines on HCV
treatment for PWID in several European countries, with
only 27 % of them reporting that active drug users had
access to HCV treatment [17].
As they have struggled to overcome barriers to HCV
treatment for PWID, cohorts of untreated HCV-infected
PWID have been aging, with a significant proportion of
untreated PWID developing cirrhosis, and even hepatocel-
lular carcinoma, at 20–30 years post-infection [18, 19]. Up
to 25 % of deaths among PWID have already been
connected to HCV infection [18]. Treatment options have
dramatically improved, however, so urgent action is needed
to increase access to treatment and optimize the circum-
stances for its uptake in PWID.
Several updated international treatment guidelines call
for HCV treatment for PWID, primarily for two reasons:
to prevent life-threatening diseases on the individual
level and—using a public health approach—to prevent
the further spread of HCV infection. The 2015 European
Association for the Study of the Liver (EASL) guidelines
regard treatment for active HCV-infected PWID as a
priority due to the risk of their transmitting HCV [20].
The 2015 International Network for Hepatitis in Sub-
stance Users (INHSU) recommendations for the man-
agement of HCV infection in PWID demonstrated that
HCV treatment among PWID is feasible and provided a
framework for HCV assessment and care in this group
[21]. High prices of the new direct-acting antivirals,
however, present the largest barrier to expanding HCV
treatment among PWID in the majority of European
countries. Yet, in spite of this, some countries, including
Iceland, Portugal, Scotland and Spain have negotiated
lower prices and initiated elimination campaigns.
To overcome remaining barriers, stronger national
HCV treatment policies are needed, along with efforts to
increase knowledge and reduce misconceptions among
physicians regarding the feasibility and importance of
treating HCV infected PWID. Treating HCV in PWID
will save lives, reduce the potential disease burden in the
future and lower costs to the healthcare systems in the
long run. And, importantly, it will also be a crucial first
step toward elimination of HCV.
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Effective prevention of hepatitis C among people
who inject drugs
Astrid Leicht, Fixpunkt e.V., Berlin, Germany
The Berlin Manifesto on Hepatitis C and Drug Use [1]
calls for the scale-up of harm reduction and, in particu-
lar, opioid substitution therapy (OST) and needle and
syringe programs (NSP). Taking into consideration the
easy transmission of hepatitis C (HCV) in comparison
to HIV, the Manifesto highlights the need to ensure
higher quality standards and coverage for harm reduc-
tion services in order to prevent HCV.
Needle and syringe programs and OST, along with
the provision of comprehensive information, edu-
cation and HIV/HCV pre/post-test counseling, are
recommended interventions by WHO, UNAIDS, the
United Nations Office on Drugs and Crime (UNODC)
[2], the European Centre for Disease Prevention and
Control (ECDC) and the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA) [2, 3, 4].
Nevertheless, in most European countries, NSP remain in
the shadows, neglected by national officials and inter-
national funders, as evidenced by the fact that the number
of programs (coverage) is often too low in most European
countries [6] as well as throughout the rest of the world
[5], if they exist at all. In some instances, NSP are given
low priority even by drug use treatment organizations.
One new development impacting prevention services
is the treatment as prevention paradigm, which empha-
sizes the cure, rather than prevention of HCV infections.
This scenario engages people who inject drugs (PWID)
in their own treatment and cure. This groundbreaking
development is positive, but it also has a “perverse” ef-
fect, in that, some infected individuals who have been
treated and cured might begin to feel safe and therefore
may risk reinfection if they do not use clean needles and
syringes, or move from injecting drugs to OST. Some
harm reduction organizations appear to overlook the
treatment as prevention approach, and instead invest in
prevention activities that are considerably less expen-
sive —and potentially less effective—than direct-acting
antivirals (DAAs).
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Scientific experts and practitioners working in the field
of harm reduction have not discussed interventions that
might be more effective in preventing both HIV and
HCV even though such discussions have taken place
around medical treatments (OST, DAA) and psycho-
social interventions. An exception is research related to
low dead-space (LDS) syringes and needles. WHO has,
in fact, rated evidence in this field as being of “very low
quality” [5]. We therefore are in serious need of in-depth
investigations into interventions that might be effective
in preventing both HIV and HCV.
 Europe is now facing a serious challenge of
improving the effectiveness and coverage of its
needle and syringe distribution facilities, often due
to budget cuts in regard of the economical crisis.
In our experience at Fixpunkt, confirmed by experts
from other organisations in Germany and within
the European wide Correlation network [8], NSP
have had limited success for the following reasons:
Needles and syringes that the health department
provides PWID are often made of inferior quality
materials or are not appropriate for their needs.
Poor-quality needles, for example, become blunt
after one pinprick, and users often need more than
one attempt to hit a vein. Program staff members
are not able to consult with their clients on the
kind of needles or syringes that they need and must
accept the standard, poor-quality materials offered
by the health department. Health department budget
constraints, in addition to the department’s apparent
lack of interest in improving the quality of materials
used, are among the reasons for this ongoing
concern.
 Additional injection equipment to prevent virus
transmission (for example, water, filters and spoons)
and hygiene products (for example, hand and surface
disinfectants and safe disposal boxes for used needles)
are often not available.
 Coverage is insufficient because of inadequate
budgets and ideological barriers that limit programs’
hours of operation and number of geographical
locations (especially in rural or remote areas) and
because of other restrictions (for example, only
one-to-one exchanges are permitted, and sale of
materials is not permitted to under-age individuals).
 NSP are headed by staff members who often do
not have adequate knowledge of the issue; funding
for training is often limited, and organizations
themselves often do not fully appreciate the need
for in-depth training. Furthermore, because of
insufficient training, many staff members are
unable to adequately inform and motivate PWID
on how to correctly use prevention equipment and
consumption materials in a safe manner and on
how to protect themselves from blood-borne
infections like viral hepatitis and HIV.
 In most prisons, access to sterile injection
equipment is unavailable.
 Police checks and other interventions by law
enforcement hinder access to NSP and create
fear among PWID who seek NSP services.
A range of effective NSP service modalities can be uti-
lized to complement and reinforce current prevention
efforts, including primary NSP and peer-based (second-
ary) NSP; pharmacy-based syringe vending machines;
mobile and outreach services; and distribution in prison
settings. Based on our experience at Fixpunkt, effective
NSP are:
 Programs that are accepted and actively supported
by all key stakeholders (for example, politicians,
funders and police);
 Programs that offer high quality materials (needles,
syringes, paraphernalia, disinfectants) for preventing
transmission of infections;
 Programs that can efficiently provide prophylactic
and/or therapeutic motivation to reinforce PWIDs’
ability to take care of their health and avoid (re-)
infection being directly (on site) linked to additional
interventions (supervised consumption, information
and training of drug users)
Neglecting simple preventative measures can have far-
reaching consequences. In Berlin, for example, 591 new
HCV infections were detected in 2014. If the level of
funding of needles, syringes and other sterile or hygienic
materials had reached that of the amount spent on only
four or five HCV treatments each year, Berlin’s harm re-
duction services would have been able to reach a much
larger number of people.
With such experiences in mind, we, as service pro-
viders, propose that, for each euro invested in medical
treatment, one cent should be invested in prevention,
mainly through the distribution of needles, syringes and
other hygienic consumption materials.
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